Discontinuation Approach and Follow-Up of Low-Concentration Atropine for Myopia Progression

Does tapering vs stopping 0.05% atropine for treatment of myopia result in less progression over 3 years?In the Low-Concentration Atropine for Myopia Progression (LAMP) randomized clinical trial, children in the taper group had less myopia progression than those in the stop group over 3 years. Older age and less myopia were associated with less myopia progression, while younger children with more myopia benefited more from the taper approach.These findings support tapering atropine concentration before treatment discontinuation, particularly for children at a younger age and with more severe myopia.

Corresponding Author: Jason C. Yam, MD, Department of Ophthalmology and Visual Sciences, The Chinese University of Hong Kong, Hong Kong Eye Hospital, 147K Argyle St, Kowloon, Hong Kong (yamcheuksing@cuhk.edu.hk).

Link to the article in your story

We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)

Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Need more information? Contact us.